The 3 Best Biotech Stocks to Buy for 2018


Investors looking for profits in the healthcare sector had a difficult time in 2017 if they weren’t in biotech. The Health Care SPDR ETF (NYSE: XLV) only gained 13.15% last year, while the S&P 500 climbed 22.5% over the same time period.

But the biotech sector crushed the market, with the SPDR S&P Biotech ETF (NYSE: XBI) returning a market-beating 43.36% in 2017, nearly double the broader S&P 500.

That’s why we’ll show you the three best biotech stocks to buy for 2018.

Despite the exceptional run for biotech stocks in 2017, the broader healthcare sector has been facing a strong headwind over the past few years that scared away some investors.

Drug pricing controversies, increased generic competition for blockbuster drugs, and the recent merger between retail giant CVS Health Corp. (NYSE: CVS) and insurance company Aetna Inc. (NYSE: AET) have weakened returns for shareholders.

Leave a Reply

Your email address will not be published.